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Antibiotic treatmentAbstract Despite advances in antimicrobial therapy, CAP remains the seventh leading cause of
death in USA. Procalcitonin (PCT) is the pre-hormone of calcitonin, which is normally secreted
by the C cells of the thyroid in response to hypercalcemia, its concentration was signiﬁcantly
increased in CAP. In lower respiratory tract infections, measuring serum PCT may aid physicians
in differentiating between typical bacterial and non-bacterial causes of inﬂammation, using a cut-off
value of 0.5 ng/mL and serum PCT guidance can reduce total antibiotic use. Furthermore, serum
PCT is useful in predicting bacteraemia and in assessing disease severity in CAP patients.
Aim of the work: To determine the usefulness of procalcitonin as a predictor of etiology and
prognosis in patients with CAP.
Patients and methods: This study was conducted at Tanta University Hospital over 50 patients
with clinical and radiological ﬁndings compatible with CAP, 25 mild and moderate CAP and 25
severe pneumonia, thorough history taking, full Clinical examination, plain Chest X-ray, arterial
blood gases, sputum samples for Gram stain and culture, blood samples for procalcitonin level mea-
surement by monoclonal immunoluminometric assay was done.
Results: There was a statistically signiﬁcant rise of PCT in severe CAP as its mean levels were
4.7 ± 0.5 and 11.9 ± 27 ng/ml in mild and severe CAP groups respectively, with a positive
correlation between the level of PCT and the severity of CAP. There was a statistically signiﬁcant
rise of PCT in typical pneumonia with a mean level of 9.9 ± 2.24 ng/ml in comparison to atypical
pneumonia with a mean level of 3.2 ± 1.96.
Conclusion: PCT measurement may provide an important indicator of severity for patients with
CAP, also it can assess treatment response in these patients.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Despite advances in antimicrobial therapy, rates of mortality
due to pneumonia have not decreased signiﬁcantly. Patients
with certain coexisting illnesses as COPD, diabetes mellitus,
congestive heart failure (CHF), coronary artery disease, activerculosis.
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ease, have an increased incidence and mortality of CAP.
CAP is deﬁned as ‘‘an acute infection of the pulmonary par-
enchyma that is associated with at least some symptoms of
acute infection, accompanied by the presence of an acute inﬁl-
trate on a chest radiograph or auscultatory ﬁndings consistent
with pneumonia (such as altered breath sounds and/or local-
ized rales), in a patient not hospitalized or residing in a long-
term care for more than 14 days before the onset of symptoms.
Most patients have nonspeciﬁc symptoms such as fatigue,
headache, myalgia, anorexia and symptoms of pneumonia
may include fever or hypothermia, sweating, rigors, dyspnea,
chest discomfort, new cough with or without expectoration,
or a change in the color of sputum in patients with chronic
cough [1,2].
First data regarding the increasing procalcitonin (PCT) con-
centration in the blood during inﬂammation were obtained by a
group of French military doctors (Dr. Carsin, etc.), who studied
markers of acute lung injury in patients with extensive burns; its
concentration was signiﬁcantly increased in many cases.
Retrospective analysis revealed that patients with the
highest levels of procalcitonin in blood had infectious compli-
cations, including sepsis and septic shock [3].
PCT is the pre-hormone of calcitonin, which is normally
secreted by the C cells of the thyroid in response to hypercal-
cemia; under normal conditions, negligible serum PCT concen-
trations are detected [4]. The mechanism proposed for PCT
production after inﬂammation and its role are still not com-
pletely known. It is believed that PCT is produced by the liver
[5] and peripheral blood mononuclear cells [6], modulated by
lipopolysaccharides and sepsis-related cytokines.
Among several markers of inﬂammation and sepsis, PCT is
studied to investigate its role and accuracy for the diagnosis of
bacterial infections. PCT is a 116 amino acid peptide with no
known hormonal activity [7]. In lower respiratory tract infec-
tions, measuring serum PCT may aid physicians in differenti-
ating between typical bacterial and non-bacterial causes of
inﬂammation, using a cut-off value of 0.5Æng/mL [8] and serum
PCT guidance can reduce total antibiotic use [9]. Furthermore,
serum PCT is useful in predicting bacteraemia and in assessing
disease severity in patients with community-acquired pneumo-
nia [10].
Most children with CAP are treated with antibiotics with-
out determination of the causative agent leading to a consider-
able over-use of antibiotics that increases the risk of bacterial
resistance, the incidence of drug-related adverse events, and
therapeutic costs [11]. A number of trials have been made to
differentiate viral and bacterial infections, and rationalize
antibiotic use by means of easily determined biomarkers [12].
Procalcitonin stands out as one of the most accurate sepsis
markers, with a superior diagnostic utility in sepsis compared
with C-reactive protein, interleukin-6, and lactate [3,13]. PCT
level was more sensitive (88% vs. 75%) and more speciﬁc
(81% vs. 67%) than CRP level for differentiating bacterial
from non-infective causes of inﬂammation [3].
High procalcitonin concentrations are both sensitive and
speciﬁc for the diagnosis of sepsis. P. Hausfater et al. evaluated
the sensitivity, speciﬁcity, and predictive value of the PCT for
identifying cases of systemic infection in patients attending an
emergency department. PCT concentrations assay were mea-
sured in serum samples by use of an immunoluminometricassay (LUMI test PCT; Brahms Diagnostica). The detection
limit of the assay was 0.08 ng/mL, and the functional sensitiv-
ity (inter assay variation coefﬁcient, 20%) was 0.33 ng/mL.
The upper limit of normal was 0.5 ng/mL. All samples were
tested in duplicate. They reported that the procalcitonin level
has excellent speciﬁcity (0.99) but a sensitivity of only 0.35
(with use of a cutoff point of 0.5 g/mL) for the diagnosis of
systemic infection. However, lowering the procalcitonin cutoff
point to 0.2 ng/mL led to improved sensitivity (0.62) with per-
sistent good speciﬁcity (0.88) [14].
Identifying the etiology of community-acquired pneumonia
(CAP) is a clinical difﬁculty because single clinical, radiologic,
or laboratory parameters have limited value to predict the
infectious organism [3], and no rapid test has been standard-
ized for the diagnosis of ‘‘atypical’’ or viral pathogens, so
empirical broad-spectrum antibiotic therapy is usually chosen
[4,5]. Serum PCT levels might help clinicians to choose proper
antibiotic by differentiating between classic bacterial and atyp-
ical or viral etiology [15].
Aim of the work
The aim of the work was to determine the usefulness of procal-
citonin as a predictor of etiology and prognosis in patients
with CAP.
Patients and methods
This study was conducted at Tanta university Hospital over a
12 month period from December 2012 to December 2013 over
50 patients with clinical and radiological ﬁndings compatible
with CAP, 25 mild and moderate CAP (12 males and 13
females) with a mean age of 47 ± 3.43 years and 25 severe
pneumonia (11 males and 14 females) with a mean age of
45 ± 3.21 years. Four were on mechanical ventilation with
no mortality.
Inclusion criteria
CAP was deﬁned as an acute illness associated with at least one
of the following symptoms as fever, new cough with or without
sputum production, pleuritic chest pain, dyspnea, or change in
the color of sputum in patients with chronic cough or signs as
altered breath sound, rales, plus chest X ray showing an opac-
ity compatible with acute pneumonia [1,2].
Criteria for severe CAP
Minor criteria
(1) Confusion/disorientation.
(2) Respiratory rate >30 breaths/min.
(3) Heart rate >120 beat/min.
(4) Hypotension requiring aggressive ﬂuid resuscitation.
(5) Hypothermia (core temperature, <36 C).
(6) Multilobar inﬁltrates.
(7) Leucopenia (WBC count <4000 cells/mm3).
(8) Uremia (BUN level, >20 mg/dL).
(9) PaO2/FiO2 ratio <250.
(10) Thrombocytopenia (platelet count,<100,000 cells/mm3).
873Major criteria
Table 1 Baseline characteristics and serum PCT levels in the
studied groups.
Group 1 Group II P
Age 47 ± 3.43 45 ± 3.21 NS
Male 12 11 Ns
Female 13 14 N S
Serum PCT level ng/ml 4.7 ± 0.5 11.9 ± 27* S*
* Signiﬁcant.
Table 2 Statistical comparisons of serum PCT (ng/ml) in
typical and atypical CAP.
Serum prolactin (ng/ml)
Atypical pneumonia Typical pneumonia
Range 02.5–3.9 4.5–14.3
Mean ± SD 3.2 ± 1.96 9.9 ± 2.24*
t Test 7.33
P <0.001
* Signiﬁcant.
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Figure 2 Statistical comparisons of serum PCT (ng/ml) in
typical and atypical CAP.
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Figure 1 Statistical comparisons of serum levels of PCT in mild
(group I) and severe (group II) CAP.(1) Invasive mechanical ventilation.
(2) Septic shock with the need for vasopressor.
Other criteria to consider
(1) Hyponatremia.
(2) Cirrhosis, asplenia.
(3) Unexplained metabolic acidosis or elevated lactate level.
Any patient with an acute illness and symptoms suggesting
lower respiratory tract infection, including new cough with
high fever or chills, pleuritic chest pain, dyspnea, or prolonged
fever was evaluated clinically and radiologically. CAP was
diagnosed if the patient fulﬁlled the criteria for pneumonia
and the pneumonia had occurred at home or within 48 h of
admission to hospital without residence in a long-term care
facility.
Exclusion criteria
(1) Patients with a prior hospitalization within 2 weeks of a
current diagnosis of pneumonia.
(2) Residence in a long-term care facility.
(3) Antibiotic use in the prior 14 days.
All subjects were subjected to thorough history taking, full
Clinical examination, chest X-ray and CT in some cases, rou-
tine laboratory investigations, arterial blood gases, sputum
sample and tracheal aspirate in mechanically ventilated
patients for culture and sensitivity, serology test for
Chlamydia pneumoniae, Legionella species, Coxiella burnetii
and Mycoplasma pneumoniae a fourfold or greater antibody
rise by complement ﬁxation test for deﬁnition of atypical pneu-
monia were performed.
PCT assay requires 20 ll of plasma, 5 ml blood sample
collected within the ﬁrst 24 h of admission, centrifuged, and
frozen at 80 C until analyzed. PCT levels were measured
by monoclonal immunoluminometric assay (Liaison Brahms
PCT; Brahms Diagnostica GMBH; Berlin, Germany). This
immunoluminometric assay is based on the reaction of two
antigen-speciﬁc monoclonal antibodies that bind PCT (as an
antigen) to calcitonin and katacalcin segments. The inter-
assay precision of the kit is 3–6.6%, the lower limit of detec-
tion is 0.02 ng/mL and the normal range is less than
0.5 ng/mL [16].
All patients were followed up for at least 4 weeks or until
death. A repeat chest X-ray and blood sample for PCT assay
were obtained from 2 to 4 weeks after the initial diagnosis of
CAP.
Results
There were no signiﬁcant differences regarding age and sex
between the 2 studied groups but there was statistical signiﬁ-
cant rise of PCT level in severe CAP (group II) than mild
CAP (group I) (Tables 1 and 2).
Role of procalcitoninThere was a statistical signiﬁcant rise of PCT in typical
pneumonia with a mean level 9.9 ± 2.24 ng/ml in comparison
to atypical pneumonia with a mean level 3.2 ± 1.96 ng/ml
(Figs. 1–3).
There was positive correlation between the level of PCT
and the severity of CAP.
01
2
3
4
5
0 2 4 6
Serum Procalcitonin level (ng/ml)
pn
eu
m
on
ia
 s
ev
er
ity
 in
de
x
Figure 3 Correlation between serum procalcitonin and severity
of pneumonia.
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F Moulin et al. found that PCT concentration, with a thresh-
old of 1 lg/l is more sensitive and speciﬁc and has greater pos-
itive and negative predictive values than CRP, IL-6, or white
blood cell count for differentiating bacterial and viral causes
of CAP in untreated children admitted to hospital as emer-
gency cases. Previous studies of community-acquired pneumo-
nia reported that the highest pro-calcitonin concentrations
were in patients with pneumonia due to classic bacterial patho-
gens, rather than in patients with atypical or viral pneumonia
[17,18].
Etiologic diagnosis of febrile patients who present to an
emergency department is complex and sometimes difﬁcult.
Physicians have to identify and often rapidly treat patients
with systemic infection. as most microbiological test results
are not available for 24 h, a sensitive and speciﬁc marker of
systemic infection would be useful [19]. In 1993, Assicot
et al. reported a correlation between a high serum level of pro-
calcitonin and sepsis [20].
It has been reported that serum PCT determination may
help to discriminate between septic and non-septic underlying
disease in ARDS [21]. However, a more recent study con-
cluded that serum PCT cannot reliably differentiate sepsis
from non-infectious causes of systemic inﬂammatory response
syndrome in critically ill adult patients [22]. At present, there
are few data addressing the usefulness of PCT to predict etiol-
ogy in patients with CAP [18]. Recently, Christ-Crain et al.,
[23] found that a procalcitonin-based therapeutic strategy
was useful to reduce antibiotic use in lower respiratory tract
infections, based on the ability of PCT to discriminate between
patients with or without clinically relevant bacterial infection.
Similarly, PCT serum levels were found to be higher in bacte-
rial versus viral or atypical etiologies in two studies of CAP
[17,18]. In contrast, in other studies [8,2426], no differences
were found in PCT levels between bacterial and nonbacterial
etiologies. The results of studies on pneumonia suggest that
PCT is a good predictor of the disease severity. After admis-
sion to the hospital, patients’ serum total PCT progressively
declined concomitantly with the clinical resolution of the
pneumonia; at discharge, on discharge the patients who had
persistent radiographic abnormalities had signiﬁcantly higher
levels than did those who had complete resolution [8,27].
The most precise way to diagnose bacterial infections is by cul-
ture; tests to conﬁrm viral infections include determination of
acute and convalescent phase antibody titers and tests for viralantigens. However, there is often a delay until results are
known, and rapid immunological or genomic tests require
prior knowledge of the infectious agent. The identiﬁcation of
markers for the early recognition of bacterial infections could
guide treatments, reduce misuse of antibiotics, and possibly
improve long-term outcomes [28]. In HAP, CAP and, to a les-
ser extent, AECB, but not TB, signiﬁcantly elevated median
PCT levels were found compared to controls. However, med-
ian PCT levels in all groups were below the recommended
cut-off level of 0.5 ng/mL. Therefore, according to the present
study, PCT concentration seems not to be particularly useful
for the detection of lower respiratory tract infections.
In the recent publication of Brunkhorst et al. reported ele-
vated PCT levels in patients with severe pneumonia; also PCT
concentration was found to be of moderate prognostic value
[29]. Concerning the usefulness of PCT concentration as a
diagnostic parameter, Hausfater et al. [14] showed that sensi-
tivity was low (in contrast to a high speciﬁcity) with the use
of a cut-off level of 0.5 ng/mL, but that improved sensitivity
could be obtained after reducing the cut-off level. They
concluded that the PCT threshold could be lower than that
proposed for critically ill patients. Similar results were seen
in the present study, in which PCT levels showed signiﬁcantly
elevated values below the cut-off level in patients with severe
CAP compared to the mild group. However, Hausfater et al.
included patients from an emergency department who had
heterogeneous infectious diseases. It was suspected that PCT
could be useful for screening emergency-department patients
with more severe infections, since good correlation of PCT
concentration was seen with the prognosis of patients suffering
systemic infections [14].
Furthermore, Fleischhack et al. [30] found a higher
sensitivity and speciﬁcity of PCT in comparison to CRP in
the diagnosis of high-risk Gram-negative bacteremia in
neutropenic pediatric patients. PCT concentration is believed
to be a sufﬁcient parameter for differentiation between severe
systemic bacterial and nonbacterial infections [31]. These
results agree with the present study, as PCT concentration
was signiﬁcantly higher in typical pneumonia than atypical
one. A similar conclusion was drawn by Toikka et al. [24]
who reported a signiﬁcant rise in PCT levels in children with
bacterial than viral pneumonia and it was in the case pertain-
ing to the extreme value in the CAP group, the clinical condi-
tion of the patient was found to deteriorate progressively. As a
result, in later stages, the criterion of sepsis was evident,
explaining the high level of PCT [20]. Castelli et al. reported
that patient deteriorating progressively with evident criteria
of sepsis, had a high PCT level, with a positive correlation
between serum PCT concentration and the severity of infec-
tion, clinical course, and mortality [32].Conclusion
PCT measurement may provide an important indicator of
severity for patients with CAP, also it can assess treatment
response in these patients.Conﬂict of interest
There is no conﬂict of interest.
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